Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

Summary

The safety and effectiveness of AmBisome 15 mg/kg, given over 15 days in 5 biweekly infusions of 3 mg/kg on an outpatient basis, is evaluated in clinically diagnosed PKDL patients of 12 years and older in a highly endemic area in Bangladesh. This is a prospective study, with the objective to assess final cure 12 months after treatment.

Timeline

Start

2014-04-08

Primary completion

2015-10-14

Completion

2015-10-14

Drugs

Indications